Racial Disparity in Non-Hodgkin Lymphoma: Parallel Survival Analysis with Data from the DoD Central Cancer Registry and SEER.

in Annals of epidemiology by Jie Lin, Alexander A Dew, Craig D Shriver, Kangmin Zhu

TLDR

  • The study found that universal access to healthcare, as provided by the MHS, may reduce racial disparities in survival outcomes for Non-Hodgkin Lymphoma patients, whereas Black patients in the U.S. general population exhibited significantly worse survival outcomes.

Abstract

Barriers to health care access may contribute to the poorer survival of Black patients with Non-Hodgkin Lymphoma (NHL) than their White counterparts in the U.S. general population. The Department of Defense's (DoD) Military Health System (MHS) provides universal or equal health care access to all its beneficiaries. This study compared overall survival of NHL patients by race in the MHS and U.S. general population, respectively, and aimed to provide evidence on the role of universal health care in reducing racial disparity. The MHS Patients were identified from the DoD's Central Cancer Registry (CCR) and the patients from the U.S. general population were identified from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program. A retrospective cohort study was conducted comparing survival of major NHL subtypes by race in the CCR and the SEER cohorts, respectively. Non-Hispanic Black patients and Non-Hispanic White patients in the CCR cohort had similar survival in Cox regression models sequentially adjusted for different sets of confounders. The hazard ratios (HRs) and 95% confidence intervals (CIs) comparing Black to White patients for diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and other NHLs were 1.25 (0.89-1.78), 0.74 (0.39-1.42), and 1.25 (0.89-1.77) in the full models, respectively. In contrast, Black patients in the SEER cohort exhibited significantly worse survival than White patients in all models adjusting for the same sets of confounders. The HRs were 1.46 (95% CI= 1.40-1.52), 1.57 (95% CI=1.48-1.67), and 1.61 (95% CI=1.54-1.68) in the full models for DLBCL, CLL/SLL and other NHL, respectively. Conclusions Our study supported universal access to health care as an important factor in reducing survival racial disparity among NHL patients.

Overview

  • The study aimed to compare overall survival of Non-Hodgkin Lymphoma (NHL) patients by race in the Department of Defense's Military Health System (MHS) and the U.S. general population.
  • The study compared survival outcomes of NHL patients in the MHS, which provides universal health care access, to those in the U.S. general population, which has varying access to healthcare.
  • The study aimed to investigate the role of universal health care in reducing racial disparities in survival outcomes for NHL patients.

Comparative Analysis & Findings

  • Similar survival outcomes were observed among Non-Hispanic Black and Non-Hispanic White patients with NHL in the MHS, with hazard ratios (HRs) ranging from 0.74 to 1.25.
  • In contrast, Black patients in the U.S. general population (SEER cohort) exhibited significantly worse survival outcomes than White patients, with HRs ranging from 1.46 to 1.61.
  • These findings suggest that universal access to healthcare, as provided by the MHS, may be an important factor in reducing racial disparities in survival outcomes for NHL patients.

Implications and Future Directions

  • The study's findings support the importance of universal access to healthcare in reducing racial disparities in health outcomes.
  • Future studies could explore the impact of healthcare access on survival outcomes for NHL patients in other populations, such as Medicare or Medicaid recipients.
  • The study's results may also inform policies aimed at improving healthcare access and reducing racial disparities in healthcare outcomes.